Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frexalimab vs Teriflunomide in Relapsing Multiple Sclerosis
NCT06141473Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Dec 2023
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 41
01
Overview
Phase 3, randomised, double-blind trial of frexalimab in multiple sclerosis (MS) (2 arms), sponsored by Sanofi. Primary endpoint: Annualized relapse rate at Week 156. Started Dec 2023; status: active, not recruiting.
02
Drugs
frexalimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06141473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141473.